This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 4, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on
Thursday, November 7, 2013, at
4:30 p.m. Eastern Time to discuss its third quarter 2013 financial results. The conference call will follow the release of the Transcept third quarter 2013 financial results after the close of market that day.
Conference Call Information
Thursday, November 7, 2013Time:
4:30 p.m. ETDial-in (U.S.): (877) 638-4558Dial-in (International): (914) 495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at
www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call and will be available through
December 31, 2013.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience. The company's lead development candidate is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug. Preclinical data suggest that TO-2070 may offer significant migraine treatment benefits beyond those provided by less convenient and more invasive DHE drug delivery methods, such as injection, liquid nasal sprays or pulmonary inhalation.
In addition to advancing TO-2070, Transcept is continuing to evaluate opportunities to supplement its development pipeline with new programs appropriate to its area of expertise. The company's management team developed Intermezzo® from concept to its approval by the FDA in 2011. Purdue holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit
www.transcept.com. For information about Intermezzo, please visit